More information about this trial is available on clinicaltrials.gov
Results have been published in Nature Medicine! See the results here.
Weill Cornell Medicine Neurological Surgery is proud to introduce an innovative new clinical trial for recurrent brain tumors. Using a combination of the latest in viral therapy and immunotherapy, this trial (called CAPTIVE) uses an adenovirus and an immune checkpoint inhibitor to tackle GBM or gliosarcoma tumors that recur after initial treatment.
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the intravenous administration of an immune checkpoint inhibitor given every three weeks for up to two years or until disease progression.
Principal Investigator: Rohan Ramakrishna, MD
Contact: Marissa Michael, mam4001@med.cornell.edu
More information about this trial is available on clinicaltrials.gov
Results have been published in Nature Medicine! See the results here.
